Geyer CE, Sikov WM, Loibl S. Reply to the Letter to the Editor "Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer" by A. Okines and N. Turner. Ann Oncol 2022 Apr 4. pii: S0923-7534(22)00671.
PMID: 35390464